8-K: BridgeBio Pharma Reports Positive Q4 and Full Year 2024 Results Driven by Attruby Launch and Pipeline Progress

BridgeBio Pharma announces its Q4 and full year 2024 financial results, highlighting the successful launch of Attruby and advancements in its clinical pipeline.

Summary

• BridgeBio Pharma reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Attruby, a TTR stabilizer for ATTR-CM, has seen 1,028 unique patient prescriptions written by 516 unique prescribers since FDA approval.
• Acoramidis was approved as BEYONTTRA in the EU, triggering a $75 million milestone payment and tiered royalties starting in the low-thirties percent.
• Acoramidis demonstrated a 59% hazard reduction on the composite endpoint of all-cause mortality and first cardiovascular-related hospitalization in the variant ATTR-CM population by month 30.
• Three global registrational studies (FORTIFY, CALIBRATE, and PROPEL 3) are fully enrolled, with last participant last visit expected before the end of 2025.
• The company ended the fourth quarter with $681 million in cash, cash equivalents, and short-term restricted cash.
• BridgeBio expects to receive $105 million in regulatory milestones in the first half of 2025 from acoramidis approvals in Europe and Japan.
• Revenue for the year ended December 31, 2024, was $221.9 million, compared to $9.3 million for the same period in the prior year.
• Operating costs and expenses for the year ended December 31, 2024, were $814.9 million, compared to $616.7 million for the same period in the prior year.
• The company recorded a net loss attributable to common stockholders of $535.8 million for the year ended December 31, 2024, compared to $643.2 million for the year ended December 31, 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong commercial progress for Attruby, key regulatory approvals, and advancements in the clinical pipeline. While the company reported a net loss, the overall tone is optimistic due to the significant revenue growth and pipeline progress.

Positives

• Successful launch of Attruby with significant prescription uptake.
• EU approval of Acoramidis (BEYONTTRA) and associated milestone payment and royalties.
• Positive clinical data for Acoramidis in variant ATTR-CM patients.
• Advancement of the clinical pipeline with full enrollment in three Phase 3 studies.
• Strong cash position of $681 million.
• Significant increase in revenue for the full year 2024.

Negatives

• The company reported a net loss attributable to common stockholders of $535.8 million for the year ended December 31, 2024.
• Operating costs and expenses increased to $814.9 million for the year ended December 31, 2024, primarily due to commercialization efforts for Attruby and R&D expenses.

Risks

• The company's success depends on the commercial success of Attruby and the positive results of ongoing clinical trials.
• Regulatory approvals are not guaranteed, and the FDA or other regulatory agencies may not agree with the company's strategies.
• The company faces competition in the biopharmaceutical industry.
• Macroeconomic and geopolitical events could impact business operations and expectations.

Future Outlook

BridgeBio anticipates potential approval of Attruby in Japan in 1H 2025 and expects topline results from FORTIFY, CALIBRATE, and PROPEL 3 studies in 2H 2025.

Management Comments

• Matt Outten, Chief Commercial Officer of BridgeBio, stated that he is very encouraged by the strength of the Attruby launch.
• Neil Kumar, Ph.D., Founder and CEO of BridgeBio, stated that it is exciting to see patients, physicians, and payers resonate with the message that the greater levels of TTR stabilization that Attruby delivers can be of benefit to the patients we serve.

Industry Context

BridgeBio's focus on genetic diseases and its development of Attruby, a near-complete TTR stabilizer, positions it as a key player in the biopharmaceutical industry, particularly in the treatment of ATTR-CM. The company's pipeline of development programs targets rare genetic disorders with unmet medical needs.

Comparison to Industry Standards

• The 90% TTR stabilization achieved by Attruby is a category-leading result compared to other TTR stabilizers on the market, such as tafamidis (Vyndaqel/Vyndamax) from Pfizer.
• The 42% reduction in all-cause mortality and recurrent hospitalizations and a 50% reduction in cardiovascular hospitalizations at 30 months with Attruby are clinically meaningful advancements compared to historical data and other treatments for ATTR-CM.
• The enrollment sizes of the FORTIFY (112 participants), CALIBRATE (71 participants), and PROPEL 3 (114 participants) trials are significant, as they represent the largest prospective interventional studies ever conducted in LGMD2I/R9 and ADH1, respectively.

Stakeholder Impact

• Shareholders: Positive news regarding revenue growth and pipeline progress may positively impact shareholder value.
• Patients: Approval and commercialization of Attruby provide a new treatment option for ATTR-CM patients.
• Employees: Continued growth and success of the company may lead to job security and potential career advancement opportunities.
• Healthcare Providers: Attruby offers a clinically meaningful advancement for ATTR-CM treatment.

Next Steps

• Anticipate Japan approval for Attruby in 1H 2025.
• Report topline results from FORTIFY, CALIBRATE, and PROPEL 3 studies in 2H 2025.
• Continue enrollment for the ACCEL run-in for a Phase 2 study of infigratinib in hypochondroplasia.
• Announce enrollment completion date for the CANaspire Phase 1/2 study of BBP-812 for Canavan disease.

Key Dates

Keywords

Attruby, Acoramidis, BEYONTTRA, ATTR-CM, LGMD2I/R9, ADH1, Achondroplasia, Clinical Trials, Phase 3, FDA Approval, EU Approval, Financial Results, BridgeBio Pharma